FDA grants quick review for 3 psychedelic drug trials

The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.

The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

It’s the latest move by the Trump administration signaling a shift in policy toward treatments that also give users a high — coming a day after the Justice Department said it would ease restrictions on state-licensed medical marijuana.

Add NBC News to GoogleFDA commissioner says decision on psychedelic treatments will be out 'quickly'05:56UK-based biotech company Compass Pathways said Friday it has received an expedited review for its experimental form of synthetic psilocybin for treatment-resistant depression. In a press release the company cited two large, phase 3 studies that had "generated positive data."